A Phase 1/2A Study of LB101 Immunotherapy in People With Solid Tumors


Full Title

A Phase 1/2a, First in Human, Open-Label, Multicenter, Dose Escalation Study with Expansion Cohorts to Evaluate the Safety, Tolerability, and Preliminary Activity of LB101 in Subjects with Advanced Solid Tumors


Researchers want to find the best dose of LB101 to use in people with advanced solid tumors. The people in this study have cancer that is inoperable (cannot be taken out) or metastatic (has spread). LB101 is designed to attach itself to the surface of cancer cells. It boosts the ability of the immune system to find and destroy cancer cells. LB101 is given intravenously (by vein).

Who Can Join

To join this study, there are a few conditions. You must:

  • Have an inoperable or metastatic solid tumor that cannot be cured with standard therapies.
  • Have recovered from the serious side effects of previous therapies.
  • Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
  • Be age 18 or older.


For more information or to see if you can join this study, please call Dr. Chrisann Kyi’s office at 646-888-4221.




Phase I/II (phases 1 and 2 combined)

Disease Status

Relapsed or Refractory




ClinicalTrials.gov ID